ATYR
aTyr Pharma, Inc. NASDAQ Listed May 7, 2015$0.92
Mkt Cap $90.4M
52w Low $0.64
4.2% of range
52w High $7.29
50d MA $0.85
200d MA $1.69
P/E (TTM)
-1.0x
EV/EBITDA
-1.0x
P/B
1.1x
Debt/Equity
0.2x
ROE
-109.8%
P/FCF
-1.2x
RSI (14)
—
ATR (14)
—
Beta
0.65
50d MA
$0.85
200d MA
$1.69
Avg Volume
1.6M
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
10240 Sorrento Valley Road · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.18 | -0.14 | +22.2% | 0.90 | -3.1% | -8.7% | -0.3% | +3.7% | +2.2% | -3.9% | — |
| Nov 6, 2025 | AMC | -0.20 | -0.26 | -30.0% | 0.77 | -2.6% | +6.0% | +2.6% | +2.2% | -6.2% | -7.4% | — |
| Aug 7, 2025 | AMC | -0.18 | -0.22 | -22.2% | 5.24 | +0.0% | +1.1% | +7.1% | -0.2% | -1.7% | -4.8% | — |
| May 7, 2025 | AMC | -0.19 | -0.17 | +10.5% | 3.16 | -1.6% | +5.7% | +3.8% | +2.5% | +4.7% | -4.1% | — |
| Mar 13, 2025 | AMC | -0.23 | -0.18 | +21.7% | 3.99 | -8.3% | -0.5% | +0.5% | -3.0% | -3.8% | -5.8% | — |
| Nov 7, 2024 | AMC | -0.22 | -0.23 | -4.5% | 3.10 | -1.6% | +0.6% | +8.4% | +12.6% | +13.5% | +2.9% | — |
| Aug 13, 2024 | AMC | -0.22 | -0.23 | -4.5% | 1.74 | +5.7% | +6.3% | +14.9% | +9.8% | +8.6% | +6.9% | — |
| May 2, 2024 | AMC | -0.24 | -0.23 | +4.2% | — | — | — | — | — | — | — | — |
| Mar 14, 2024 | AMC | -0.24 | -0.25 | -4.2% | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | -0.23 | -0.20 | +13.3% | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | -0.28 | -0.22 | +19.7% | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | -0.35 | -0.29 | +18.5% | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 7 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $0.77 | $0.75 | -2.6% | +6.0% | +2.6% | +2.2% | -6.2% | -7.4% |
| Sep 16 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $1.01 | $1.08 | +6.9% | +6.9% | +1.0% | +4.0% | -1.8% | +4.0% |
| Sep 16 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $1.01 | $1.08 | +6.9% | +6.9% | +1.0% | +4.0% | -1.8% | +4.0% |
| Sep 15 | LUCID CAPITAL MARKETS | Downgrade | Buy → Neutral | — | $6.03 | $1.26 | -79.1% | -83.3% | -82.1% | -83.1% | -82.6% | -83.5% |
| Sep 15 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $6.03 | $1.26 | -79.1% | -83.3% | -82.1% | -83.1% | -82.6% | -83.5% |
| Sep 15 | Jones Trading | Downgrade | Buy → Hold | — | $6.03 | $1.26 | -79.1% | -83.3% | -82.1% | -83.1% | -82.6% | -83.5% |
| Sep 15 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $6.03 | $1.26 | -79.1% | -83.3% | -82.1% | -83.1% | -82.6% | -83.5% |
| Sep 15 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $6.03 | $1.26 | -79.1% | -83.3% | -82.1% | -83.1% | -82.6% | -83.5% |
| Aug 22 | Jefferies | Maintains | Buy → Buy | — | $4.95 | $5.11 | +3.2% | +8.1% | +4.2% | +3.8% | +4.4% | +8.1% |
| Jun 20 | Wells Fargo | Maintains | Overweight → Overweight | — | $5.17 | $5.49 | +6.2% | +1.0% | -3.7% | +2.7% | -1.2% | +2.7% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.39 | $5.50 | +2.0% | -4.6% | -0.7% | -0.2% | +1.1% | +2.0% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.27 | $3.30 | +0.9% | +5.2% | +6.7% | +14.7% | +16.2% | +14.7% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.99 | $3.66 | -8.3% | -0.5% | +0.5% | -3.0% | -3.8% | -5.8% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.53 | $3.60 | +2.0% | -6.8% | -10.2% | -14.4% | -13.3% | -14.2% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.56 | $3.56 | +0.0% | -6.5% | -6.5% | -8.1% | -5.6% | -0.8% |
| Oct 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.32 | $3.47 | +4.5% | +0.0% | -5.7% | -6.0% | -8.4% | -7.2% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.85 | $1.88 | +1.6% | +8.1% | +3.2% | +2.2% | +0.5% | +1.6% |
| Aug 14 | RBC Capital | Maintains | Outperform → Outperform | — | $1.74 | $1.84 | +5.7% | +6.3% | +14.9% | +9.8% | +8.6% | +6.9% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.98 | $2.02 | +2.0% | -1.5% | -7.6% | -5.1% | -5.6% | -10.1% |
| Jul 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.64 | $1.70 | +3.7% | +13.4% | +14.0% | +17.7% | +36.0% | +35.4% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 3 | HC Wainwright& Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 15 | RBC Capital | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Feb 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
No insider trades available.
Data updated apr 24, 2026 7:44pm
· Source: massive.com